Ascentage Pharma Group International
HKEX:6855.HK
44.2 (HKD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 221.984 | 209.711 | 27.91 | 12.45 | 14.513 | 6.807 | 6.328 | 7.667 |
| Cost of Revenue
| 30.543 | 21.998 | 3.328 | 1.966 | 2.096 | 0 | 0 | 0.261 |
| Gross Profit
| 191.441 | 187.713 | 24.582 | 10.484 | 12.417 | 6.807 | 6.328 | 7.406 |
| Gross Profit Ratio
| 0.862 | 0.895 | 0.881 | 0.842 | 0.856 | 1 | 1 | 0.966 |
| Reseach & Development Expenses
| 706.972 | 743.104 | 766.491 | 564.571 | 463.883 | 249.565 | 118.815 | 102.692 |
| General & Administrative Expenses
| 181.076 | 170.471 | 143.262 | 128.667 | 161.367 | 61.499 | 13.405 | 17.707 |
| Selling & Marketing Expenses
| 195.387 | 157.421 | 47.748 | 1.372 | 0.276 | 0 | 0 | 0 |
| SG&A
| 376.463 | 328.016 | 191.261 | 130.342 | 161.643 | 61.499 | 13.405 | 17.707 |
| Other Expenses
| -1.402 | -3.125 | -23.377 | -23.814 | -913.901 | -25.754 | -0.199 | -2.987 |
| Operating Expenses
| 1,064.077 | 1,031.827 | 847.206 | 684.895 | 1,503.365 | 330.651 | 136.996 | 122.028 |
| Operating Income
| -838.932 | -883.407 | -933.17 | -684.429 | -613.109 | -342.538 | -98.282 | -117.596 |
| Operating Income Ratio
| -3.779 | -4.212 | -33.435 | -54.974 | -42.246 | -50.321 | -15.531 | -15.338 |
| Total Other Income Expenses Net
| -93.93 | -37.362 | 37.586 | -11.507 | -869.207 | -23.065 | 10.552 | 6.783 |
| Income Before Tax
| -932.862 | -887.172 | -832.249 | -675.448 | -1,482.316 | -346.909 | -120.116 | -107.839 |
| Income Before Tax Ratio
| -4.202 | -4.23 | -29.819 | -54.253 | -102.137 | -50.964 | -18.982 | -14.065 |
| Income Tax Expense
| -7.15 | 4.248 | 49.825 | 2.158 | 1.602 | -1.602 | -1.602 | -13.016 |
| Net Income
| -925.637 | -882.924 | -782.424 | -677.606 | -1,480.714 | -345.307 | -118.514 | -107.839 |
| Net Income Ratio
| -4.17 | -4.21 | -28.034 | -54.426 | -102.027 | -50.728 | -18.729 | -14.065 |
| EPS
| -3.37 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 | -0.57 | -0.52 |
| EPS Diluted
| -3.37 | -3.35 | -3.07 | -3.14 | -12.69 | -1.67 | -0.57 | -0.52 |
| EBITDA
| -743.61 | -835.986 | -915.987 | -641.771 | -596.259 | -324.076 | -85.781 | -116.049 |
| EBITDA Ratio
| -3.359 | -3.986 | -32.819 | -53.612 | -41.084 | -47.609 | -13.556 | -15.136 |